The present invention provides for a genetically modified yeast host cell capable of producing elevated levels of 3-methyl-3-butene-1-ol or isoprenol.

The present disclosure relates to a modified polypeptide with attenuated activity of citrate synthase and a method for producing an aspartate-derived L-amino acid using the modified polypeptide.

Genetically engineered oleaginous fungi (e.g., engineered Yarrowia lipolytica) are provided for use in itaconic acid production. In some aspects, the engineered fungi comprise a transgene for expression of a cis-aconitic acid decarboxylase (CAD) enzyme and, optionally, one or more further genetic modifications. Methods and culture systems for production of itaconic acid using such fungi are also provided.

The present invention relates to a process for producing ethyl esters of polyunsaturated fatty acids, comprising transesterifying triacylglycerols in extracted plant lipid.

An object of the present invention is to provide enzymes and a DNA encoding the enzymes that are involved in biosynthesis of trehangelin which has the potential to be a therapeutic agent for photosensitivity disorder and cosmetics, and to provide a method for producing trehangelin by utilizing the enzymes and a recombinant microorganism. The present invention is directed to a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9, or a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 in which one to several amino acids are deleted, substituted, added and/or inserted or an amino acid sequence having 60% or more homology with the amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 and having an enzyme activity involved in biosynthesis of trehangelin; and a DNA encoding said protein.

Disclosed is a recombinant microorganism comprising endogenous enzymes that convert CO and/or CO.sub.2 to acetyl-CoA. The recombinant microorganism contains a heterologous nucleic acid sequence encoding one or more enzymes that allow the conversion of acetyl-CoA to an alkene with a main chain of 1 to 5 carbon atoms. The heterologous nucleic acid sequence comprises one or more coding sequences encoding one or more enzymes that catalyse the conversion of acetyl-CoA to crotonyl-CoA, and that further catalyse the conversion of crotonyl-CoA to an alkene; or one or more coding sequences encoding one or more enzymes that catalyse the conversion of acetyl-CoA to 3-methylcrotonyl-CoA, and that further catalyse the conversion of 3-methylcrotonyl-CoA to an alkene; or one or more coding sequences encoding one or more enzymes that catalyse the conversion of acetyl-CoA to propionyl-CoA, and that further catalyse the conversion of propionyl-CoA to an alkene. Each coding sequence is operationally linked to a transcriptional promoter.

The present invention relates to the field of antimicrobial agents active against Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

A coryneform bacteria cell with an increased provision of Malonyl-CoA compared to its archetype, wherein the regulation and/or expression of one or more of genes fasB, gltA, accBC and accD1, and/or the functionality of the enzyme encoded by each gene is modified in a targeted manner. The cell may have one or more targeted modifications, including reduced or eliminated functionality of the fatty acid synthase FasB, mutation or partial or complete deletion of the fatty acid synthase encoding gene fasB, and/or reduced functionality of the promoter operatively linked to the citrate synthase gene gtIA, among other targeted modifications.

The present disclosure describes the engineering of microbial cells for fermentative production of 2-oxoadipate and provides novel engineered microbial cells and cultures, as well as related 2-oxoadipate production methods.

Genetically modified LeuCD′ enzyme complexes, processes for preparing a C.sub.7-C.sub.11 2-ketoacid utilizing genetically modified LeuCD′ enzyme complexes, and microbial organisms including modified LeuCD enzyme complexes are described. The instantly-disclosed genetically modified LeuCD′ enzyme complexes, processes for preparing a C.sub.7-C.sub.11 2-ketoacid, and microbial organisms including modified LeuCD′ enzyme complexes can be particularly useful for producing C.sub.6-C.sub.10 aldehydes, alkanes, alcohols, and carboxylic acids, both in vivo and in vitro.